

Please substitute the following claims 157, 159, 162, 165, 168, 173, 176, 180, 182, 185, 188, 191, 196, 197, 199, 200, 207, 208, 210, 211, 230, 232, 233, 234, 235, 236, 237, 238, 239, 240, 242, 247, 250, 257, 258, 260, 261, 264, 273, 274, 276 and 277 for pending claims 157, 159, 162, 165, 168, 173, 176, 180, 182, 185, 188, 191, 196, 197, 199, 200, 207, 208, 210, 211, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 242, 247, 250, 257, 258, 260, 261, 264, 273, 274, 276 and 277:

157. (Once amended) An isolated polynucleotide comprising a first nucleic acid at least 95% identical to a reference nucleic acid selected from the group consisting of:

- K₁
- (a) a nucleic acid consisting of nucleotides 839 to 1048 of SEQ ID NO:1;
 - (b) a nucleic acid consisting of nucleotides 419 to 1420 of SEQ ID NO:1;
 - (c) a nucleic acid consisting of nucleotides 416 to 1420 of SEQ ID NO:1;

and

(d) a nucleic acid consisting of the nucleotides encoding the complete amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 203072.

K₂

159. (Once amended) The isolated polynucleotide of claim 157, wherein said first nucleic acid is at least 95% identical to a reference nucleic acid consisting of nucleotides 839 to 1048 of SEQ ID NO:1.

162. (Once amended) The isolated polynucleotide of claim 157, wherein said first nucleic acid is at least 95% identical to a reference nucleic acid consisting of nucleotides 419 to 1420 of SEQ ID NO:1.

165. (Once amended) The isolated polynucleotide of claim 157, wherein said first nucleic acid is at least 95% identical to a reference nucleic acid consisting of nucleotides 416 to 1420 of SEQ ID NO:1.

168. (Once amended) The isolated polynucleotide of claim 157, wherein said first nucleic acid is at least 95% identical to a reference nucleic acid consisting of the nucleotides encoding the complete amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 203072.

173. (Once amended) The vector of claim 172, wherein said polynucleotide comprises a nucleotide sequence heterologous to said first nucleic acid.

176. (Once amended) The host cell of claim 175, wherein said polynucleotide comprises a nucleotide sequence heterologous to said first nucleic acid.

180. (Once amended) An isolated polynucleotide comprising a nucleic acid encoding a first amino acid sequence at least 99% identical to a reference amino acid sequence selected from the group consisting of:

(a) amino acids 142 to 211 of SEQ ID NO:2;

K₁
cont.

- (b) amino acids 2 to 335 of SEQ ID NO:2;
- (c) amino acids 1 to 335 of SEQ ID NO:2; and
- (d) the complete amino acid sequence encoded by the cDNA clone

contained in ATCC Deposit No. 203072;

wherein said first amino acid sequence regulates Prostate-Specific Antigen (PSA) gene expression.

K₁₁

182. (Once amended) The isolated polynucleotide of claim 180, wherein said first amino acid sequence is at least 99% identical to amino acids 142 to 211 of SEQ ID NO:2.

K₁₁

185. (Once amended) The isolated polynucleotide of claim 180, wherein said first amino acid sequence is at least 99% identical to amino acids 2 to 335 of SEQ ID NO:2.

K₁₂

188. (Once amended) The isolated polynucleotide of claim 180, wherein said first amino acid sequence is at least 99% identical to amino acids 1 to 335 of SEQ ID NO:2.

K₁₃

191. (Once amended) The isolated polynucleotide of claim 180, wherein said first amino acid sequence is at least 99% identical to the complete amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 203072.

K₁₄

196. (Once amended) The vector of claim 195, wherein said polynucleotide comprises a nucleotide sequence heterologous to said nucleic acid.

K15
197. (Once amended) The vector of claim 196, wherein said heterologous sequence is operably associated with said nucleic acid and is selected from the group consisting of a promoter, a site for transcription initiation, a site for transcription termination, an enhancer, a Kozak sequence, an operator and a ribosome binding site.

K16
199. (Once amended) The host cell of claim 198, wherein said polynucleotide comprises a nucleotide sequence heterologous to said nucleic acid.

K17
200. (Once amended) The host cell of claim 199, wherein said heterologous sequence is operably associated with said nucleic acid and is selected from the group consisting of a promoter, a site for transcription initiation, a site for transcription termination, an enhancer, a Kozak sequence, an operator and a ribosome binding site.

K18
207. (Once amended) The vector of claim 206, wherein said polynucleotide comprises a nucleotide sequence heterologous to said nucleic acid.

208. (Once amended) The vector of claim 207, wherein said heterologous sequence is operably associated with said nucleic acid and is selected from the group consisting of a promoter, a site for transcription initiation, a site for transcription termination, an enhancer, a Kozak sequence, an operator and a ribosome binding site.

K19
210. (Once amended) The host cell of claim 209, wherein said polynucleotide comprises a nucleotide sequence heterologous to said nucleic acid.

K₂₁
211. (Once amended) The host cell of claim 210, wherein said heterologous sequence is operably associated with said nucleic acid and is selected from the group consisting of a promoter, a site for transcription initiation, a site for transcription termination, an enhancer, a Kozak sequence, an operator and a ribosome binding site.

K₂₁
230. (Once amended) An isolated polynucleotide comprising a nucleic acid encoding at least 100 contiguous amino acids of SEQ ID NO:2.

K₂₂
232. (Once amended) The isolated polynucleotide of claim 230, comprising a nucleic acid encoding at least 150 contiguous amino acids of SEQ ID NO:2.

233. (Once amended) The isolated polynucleotide of claim 230, further comprising a nucleotide sequence heterologous to said nucleic acid.

234. (Once amended) A method of producing a vector comprising inserting the isolated polynucleotide of claim 230 into a vector.

235. (Once amended) A vector comprising the isolated polynucleotide of claim 230.

236. (Once amended) The vector of claim 235, wherein said polynucleotide comprises a nucleotide sequence heterologous to said nucleic acid.

K22
cont.

237. (Once amended) The vector of claim 236, wherein said heterologous sequence is operably associated with said nucleic acid and is selected from the group consisting of a promoter, a site for transcription initiation, a site for transcription termination, an enhancer, a Kozak sequence, an operator and a ribosome binding site.

238. (Once amended) A host cell comprising the isolated polynucleotide of claim 230.

239. (Once amended) The host cell of claim 238, wherein said polynucleotide comprises a nucleotide sequence heterologous to said nucleic acid.

240. (Once amended) The host cell of claim 239, wherein said heterologous sequence is operably associated with said nucleic acid and is selected from the group consisting of a promoter, a site for transcription initiation, a site for transcription termination, an enhancer, a Kozak sequence, an operator and a ribosome binding site.

K23

242. (Once amended) A composition comprising the isolated polynucleotide of claim 230.

K24

247. (Once amended) The vector of claim 246, wherein said polynucleotide comprises a nucleotide sequence heterologous to said first nucleic acid.

K24
250. (Once amended) The host cell of claim 249, wherein said polynucleotide comprises a nucleotide sequence heterologous to said first nucleic acid.

K25
257. (Once amended) The vector of claim 256, wherein said polynucleotide comprises a nucleotide sequence heterologous to said nucleic acid.

258. (Once amended) The vector of claim 257, wherein said heterologous sequence is operably associated with said nucleic acid and is selected from the group consisting of a promoter, a site for transcription initiation, a site for transcription termination, an enhancer, a Kozak sequence, an operator and a ribosome binding site.

K27
260. (Once amended) The host cell of claim 259, wherein said polynucleotide comprises a nucleotide sequence heterologous to said nucleic acid.

261. (Once amended) The host cell of claim 260, wherein said heterologous sequence is operably associated with said nucleic acid and is selected from the group consisting of a promoter, a site for transcription initiation, a site for transcription termination, an enhancer, a Kozak sequence, an operator and a ribosome binding site.

K28
264. (Once amended) A polynucleotide comprising a nucleic acid fused in frame to a nucleotide sequence heterologous to SEQ ID NO:1, wherein said heterologous nucleotide sequence encodes a heterologous polypeptide, and wherein said nucleic acid is selected from the group consisting of:

K25
cont.

- (a) a nucleic acid encoding amino acids 279 to 287 of SEQ ID NO:2;
- (b) a nucleic acid encoding amino acids 292 to 300 of SEQ ID NO:2;
- (c) a nucleic acid encoding amino acids 317 to 325 of SEQ ID NO:2;
- (d) a nucleic acid encoding amino acids 239 to 247 of SEQ ID NO:2;
- (e) a nucleic acid encoding amino acids 272 to 280 of SEQ ID NO:2; and
- (f) a nucleic acid encoding amino acids 248 to 331 of SEQ ID NO:2.

K29

273. (Once amended) The vector of claim 272, wherein said polynucleotide comprises a nucleotide sequence heterologous to said nucleic acid.

274. (Once amended) The vector of claim 273, wherein said heterologous sequence is operably associated with said nucleic acid and is selected from the group consisting of a promoter, a site for transcription initiation, a site for transcription termination, an enhancer, a Kozak sequence, an operator and a ribosome binding site.

K30

276. (Once amended) The host cell of claim 275, wherein said polynucleotide comprises a nucleotide sequence heterologous to said nucleic acid.

277. (Once amended) The host cell of claim 276, wherein said heterologous sequence is operably associated with said nucleic acid and is selected from the group consisting of a promoter, a site for transcription initiation, a site for transcription termination, an enhancer, a Kozak sequence, an operator and a ribosome binding site.